Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| BORRBorr Drilling Ltd | Tor Olav TroimDirector | $2.19M | Added | |||
| Purchase via Drew Holdings Ltd (Drew Trust, non-discretionary trust of which Troim is beneficiary). Bought at $4.3868/sh avg. Now $4.50 (+2.5%). Post-buy indirect stake: 28,685,941 shares. Follows weak Q2 earnings — classic Troim dip-buy pattern. | ||||||
| ONONOn Holding AG | Bernhard OlivierCo-CEO / Executive Officer | $1.99M | Added | |||
| Open-market purchase at $30.6737 weighted avg (range $30.57–$30.78), Aug 14. Now $31.31 (+2.1%). Cluster: Co-CEO Coppetti made identical 65K-share purchase same day — combined $4.0M dual-CEO buy. | ||||||
| ONONOn Holding AG | Caspar Felix CoppettiCo-CEO / Executive Officer | $1.99M | Added | |||
| Open-market purchase at $30.6737 weighted avg (range $30.57–$30.78), Aug 14. Now $31.31 (+2.1%). Post-buy holdings: 2,440,855 shares direct. Cluster buy with Co-CEO Bernhard Olivier. | ||||||
| KURAKura Oncology, Inc. | Troy Edward WilsonPresident and CEO | $1.11M | Added | |||
| Purchase via One Fish Two Fish Revocable Trust at $11.12 weighted avg (range $10.87–$11.31). Now $11.28 (+1.4%). Post-buy total holdings across all accounts: 1,114,650 shares. CEO buying biotech at multi-month lows. | ||||||
| MLABMesa Laboratories Inc | Siddhartha KadiaPresident and CEO | $800K | Added | |||
| Private transaction from Board Chair John Sullivan at $112.80/sh (not open-market). Purchased via Anjou Parekh Lifetime Access Trust (spouse as trustee). Now $107.64 (-4.6% under water). Note: transaction code P but privately negotiated. | ||||||
| NRGVEnergy Vault Holdings, Inc. | Dylan HixonDirector | $320K | Added | |||
| Three separate purchases Aug 14: 26,845 sh via Casimir R. Hixon Trust @ $3.733 ($100,229), 26,809 sh via Soren A. Hixon Trust @ $3.733 ($100,084), 31,864 sh by son @ $3.75 ($119,490). Now $3.82 (+2.1%). Reporting person disclaims beneficial ownership of trust/son shares except to pecuniary interest. | ||||||
| REZIResideo Technologies Inc | Joshua Peter FosterSVP, GC & Corp Sec | $315K | Added | |||
| Open-market purchase at $20.57 avg on Aug 14. Now $20.64 (+0.3%). Senior legal officer buying near 52-week range lows in smart-home / connected-devices space. | ||||||
| ENHAEnhanced Group Inc | Apeiron Investment Group Ltd10%+ Owner | $296K | Added | |||
| Purchase at $1.97/sh avg on Aug 14. Now $1.71 (-13.2% under water). Apeiron is a 10%+ institutional owner adding to position; micro-cap with wide bid/ask spread. | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings. 8 qualifying buys (≥ $250K, transaction type P) totalling $9.0M.
ONON cluster buy — strongest signal of the day: Both co-CEOs of On Holding AG (Bernhard Olivier and Caspar Felix Coppetti) each bought 65,000 shares at $30.67 on August 14 — a coordinated $4.0M combined purchase by the two top executives. On Holding has pulled back from highs amid macro uncertainty; this dual-CEO conviction buy at the same price is a high-quality insider signal.
BORR dip buy: Director Tor Olav Troim (via Drew Holdings/Drew Trust) added 500K shares to an already massive ~28.7M-share indirect stake in Borr Drilling, following what media described as a weak Q2 quarter. Troim has a long track record of buying BORR dips aggressively.
KURA CEO conviction: CEO Troy Wilson bought 100K shares at ~$11 through a family revocable trust, placing $1.1M in the biotech at current levels. Kura Oncology's oral RAS inhibitor pipeline has been a volatile story — this is a sizable, meaningful CEO commitment.
MLAB private buy, note caveats: Mesa Labs CEO Kadia purchased shares directly from departing Board Chair John Sullivan in a negotiated private transaction — code P but not an open-market purchase. Still a meaningful alignment signal; shares are now 4.6% below his cost basis.
ENHA underwater: Apeiron's 150K-share purchase at $1.97 is already -13.2% in the money; Enhanced Group is a micro-cap name with wide spreads — monitor for further accumulation or position exits.
Sectors represented: Offshore drilling / energy (BORR, NRGV), Sportswear/footwear (ONON), Oncology biotech (KURA), Life science tools (MLAB), Smart home / connected devices (REZI), Consumer-tech (ENHA).
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.